Johnson & Johnson (JNJ) Return on Capital Employed (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Return on Capital Employed came in at 28.18% in Q1 2026, up 1180.0% year-on-year from 2.2% in Q1 2025, and little changed quarter-over-quarter from 28.14% in Q4 2025.
Johnson & Johnson (JNJ) Return on Capital Employed (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Return on Capital Employed across 18 years of filings, most recently posting 28.18% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 28.18%, up 1180.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 28.18% (up 1180.0% YoY), and the FY2025 annual result was 29.46%, up 1244.0% from the prior year.
- Return on Capital Employed came in at 28.18% for Q1 2026 at Johnson & Johnson, roughly flat from 28.14% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 30.16% in Q2 2024 to a low of 15.38% in Q4 2022.
- The 5-year median for Return on Capital Employed is 18.66% (2023), against an average of 21.41%.
- Peak annual rise in Return on Capital Employed reached 1183 bps in 2025, while the deepest fall reached 1476 bps in 2025.
- Johnson & Johnson's Return on Capital Employed stood at 15.38% in 2022, then surged by 95 bps to 29.97% in 2023, then tumbled by 46 bps to 16.31% in 2024, then surged by 73 bps to 28.14% in 2025, then increased by 0 bps to 28.18% in 2026.
- The last three Return on Capital Employed figures came in at 28.18% (Q1 2026), 28.14% (Q4 2025), and 16.49% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | 9.49% |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | 42.94% |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 28.18% |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 16.47% |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | -10.20% |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | -6.84% |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 28.18% |
| Dec 28, 2025 | 28.14% |
| Sep 28, 2025 | 16.49% |
| Jun 29, 2025 | 15.40% |
| Mar 30, 2025 | 16.38% |
| Dec 29, 2024 | 16.31% |
| Sep 29, 2024 | 28.35% |
| Jun 30, 2024 | 30.16% |
| Mar 31, 2024 | 30.00% |
| Dec 31, 2023 | 29.97% |
| Oct 1, 2023 | 19.98% |
| Jul 2, 2023 | 18.93% |
| Apr 2, 2023 | 18.66% |
| Jan 1, 2023 | 18.44% |
| Oct 2, 2022 | 15.38% |
| Jul 3, 2022 | 15.79% |
| Apr 3, 2022 | 17.37% |
| Oct 3, 2021 | 20.67% |
| Jul 4, 2021 | 19.67% |
| Apr 4, 2021 | 18.45% |